<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03251560</url>
  </required_header>
  <id_info>
    <org_study_id>PID201706</org_study_id>
    <nct_id>NCT03251560</nct_id>
  </id_info>
  <brief_title>The Clinical Effect of Fuke Qianjin Capsule on Chronic Pelvic Pain Caused by Pelvic Inflammation</brief_title>
  <official_title>The Clinical Effect of Fuke Qianjin Capsule on Chronic Pelvic Pain Caused by Pelvic Inflammation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aijun Sun</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Second Hospital of Jilin University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shenzhen maternal and child health care hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guangzhou Women and Children's Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Peking Union Medical College Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective random control clinical trials to research Fuke Qianjin capsule's effects on
      ameliorating the pain caused by chronic pelvic disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Fuke Qianjin capsule has been widely used in clinical medicine to ameliorate the pain caused
      by chronic pelvic disease.But random control trials on its effects are few.Our study was
      designed as a prospective random control clinical trials to research its effects.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2016</start_date>
  <completion_date type="Anticipated">December 31, 2018</completion_date>
  <primary_completion_date type="Actual">December 31, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>half of the participants will receive Fuke Qianjin capsule, the other half participants will receive placebo</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual Analogue Scale Score(VAS score) of pelvic pain</measure>
    <time_frame>5 minutes</time_frame>
    <description>pelvic pain degree related assessment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>C-reaction protein(CRP)</measure>
    <time_frame>5 minutes</time_frame>
    <description>inflammation response biomarker assessment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Interleukin 6 (IL-6)</measure>
    <time_frame>5 minutes</time_frame>
    <description>pro-inflammatory cytokine assessment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tumor necrosis factor alpha (TNFα)</measure>
    <time_frame>5 minutes</time_frame>
    <description>systemic inflammation biomarker assessment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Short Form (36) Health Survey (SF-36)</measure>
    <time_frame>5 minutes</time_frame>
    <description>health status measure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short-form McGill Pain Questionnaire (SF-MPQ)</measure>
    <time_frame>5 minutes</time_frame>
    <description>pain assessment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Chronic Pelvic Pain</condition>
  <arm_group>
    <arm_group_label>Fuke Qianjin capsule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fuke Qianjin capsule, 2 pills each time,three times a day, orally (0.4g/pill）,for 2months,</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo oral capsule</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo pills, 2 pills each time,three times a day, orally, for 2months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fuke Qianjin capsule</intervention_name>
    <description>Fuke Qianjin capsule 0.8g pills by mouth, three times daily</description>
    <arm_group_label>Fuke Qianjin capsule</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral capsule</intervention_name>
    <description>Placebo oral capsule 0.8g pill by mouth, three times daily</description>
    <arm_group_label>Placebo oral capsule</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is a female between the age of 18 and 50.

          -  Subject with a history of pelvic inflammatory disease suffered from one of the
             symptoms below and one of the signs below: symptoms:1.lower abdominal distension or
             pain;2.lumbosacral soreness. signs:1. enlarged,cable strip-like fallopian tube with
             mild tenderness palpated on one side or both sides of the uterine;2.restricted
             movement or adhesion fixed of the uterine;3.the sacral ligaments thicken and harden
             with mild tenderness.

          -  Subject VAS score of pelvic pain ≥4

          -  Subject without fertility requirements in 2 months

          -  Subject provides written informed consent.

        Exclusion Criteria:

          -  Subject underwent recurrent urinary system infection or interstitial cystitis

          -  Subject underwent irritable bowel syndrome

          -  Subject has other complications in addition to chronic pelvis inflammation diseases
             leading to chronic pelvic pain,such as gynecological malignant disease,irregular
             vaginal bleeding, endometriosis,adenomyosis,ovarian neoplasm with a diameter &gt;5cm by
             ultrasound

          -  Subject is pregnant or lactating.

          -  Subject has a severe systemic disease, such as cardiovascular system

          -  Subject has a history of malignancy or radiotherapy.

          -  Subject has undergone any chronic pelvic pain treatment including
             antibiotics,paregoric,physiotherapy or any other related treatment within 1month prior
             to randomization.

          -  Subject has mental disorder incapable of elementary cooperations.

          -  Subject has an allergic history to the experimental drug.

          -  Subject has participated in other clinical researches of medicine within 1month prior
             to randomization.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Female</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aijun Sun, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking Union Medical College Hospital,Peking Union Medical College,Chinese Academy of Medical Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lei Li, MD</last_name>
    <phone>13911988831</phone>
    <phone_ext>+86</phone_ext>
    <email>lileigh@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Lei Li</name>
      <address>
        <city>Beijing</city>
        <state>China/Beiing</state>
        <zip>100000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lei L Li, MD</last_name>
      <phone>13911988831</phone>
      <phone_ext>+86</phone_ext>
      <email>lileigh@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>https://www.uptodate.com/contents/causes-of-chronic-pelvic-pain-in-women?source=Out%20of%20date%20-%20zh-Hans&amp;search=%E6%85%A2%E6%80%A7%E7%9B%86%E8%85%94%E7%82%8E&amp;selectedTitle=4~150</url>
    <description>Causes of chronic pelvic pain in women</description>
  </link>
  <link>
    <url>https://www.clinicalkey.com/#!/content/book/3-s2.0-B9781455770083000053?scrollTo=%23hl0001217</url>
    <description>Chronic Pelvic Inflammatory Disease</description>
  </link>
  <reference>
    <citation>Steege JF, Siedhoff MT. Chronic pelvic pain. Obstet Gynecol. 2014 Sep;124(3):616-29. doi: 10.1097/AOG.0000000000000417.</citation>
    <PMID>25162265</PMID>
  </reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 13, 2017</study_first_submitted>
  <study_first_submitted_qc>August 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 16, 2017</study_first_posted>
  <last_update_submitted>February 2, 2018</last_update_submitted>
  <last_update_submitted_qc>February 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Peking Union Medical College Hospital</investigator_affiliation>
    <investigator_full_name>Aijun Sun</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <keyword>Fuke Qianjin capsule</keyword>
  <keyword>chronic pelvic pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Pelvic Pain</mesh_term>
    <mesh_term>Pelvic Inflammatory Disease</mesh_term>
    <mesh_term>Pelvic Infection</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Network platform, and the website will be attached later.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

